Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marion Flipo

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Nature Communications|January 11, 2022
Pyridylpiperazine-based allosteric inhibitors of RND-type multidrug efflux pumpsColine Plé, Heng-Keat Tam, Anais Vieira Da Cruz, et al.
Science (New York, N.Y.)|March 18, 2017
Reversion of antibiotic resistance in <i>Mycobacterium tuberculosis</i> by spiroisoxazoline SMARt-420Nicolas Blondiaux, Martin Moune, Matthieu Desroses, et al.
Npj Antimicrobials and Resistance|May 30, 2026
Exploiting DprE2 pathway redundancy to enhance potency and overcome resistance to pretomanid in Mycobacterium tuberculosisKamel Djaout, Aurore Dreneau, Léo Faion, et al.
ACS Nano|March 2, 2019
Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against TuberculosisArnaud Machelart, Giuseppina Salzano, Xue Li, et al.
Science Translational Medicine|May 4, 2022
The small-molecule SMARt751 reverses <i>Mycobacterium tuberculosis</i> resistance to ethionamide in acute and chronic mouse models of tuberculosisMarion Flipo, Rosangela Frita, Marilyne Bourotte, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Nature Communications|January 11, 2022
Pyridylpiperazine-based allosteric inhibitors of RND-type multidrug efflux pumpsColine Plé, Heng-Keat Tam, Anais Vieira Da Cruz, et al.
Science (New York, N.Y.)|March 18, 2017
Reversion of antibiotic resistance in <i>Mycobacterium tuberculosis</i> by spiroisoxazoline SMARt-420Nicolas Blondiaux, Martin Moune, Matthieu Desroses, et al.
Npj Antimicrobials and Resistance|May 30, 2026
Exploiting DprE2 pathway redundancy to enhance potency and overcome resistance to pretomanid in Mycobacterium tuberculosisKamel Djaout, Aurore Dreneau, Léo Faion, et al.
ACS Nano|March 2, 2019
Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against TuberculosisArnaud Machelart, Giuseppina Salzano, Xue Li, et al.
Science Translational Medicine|May 4, 2022
The small-molecule SMARt751 reverses <i>Mycobacterium tuberculosis</i> resistance to ethionamide in acute and chronic mouse models of tuberculosisMarion Flipo, Rosangela Frita, Marilyne Bourotte, et al.
Pageof 4